US · BCAB
BioAtla, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- bioatla.com
Price · as of 2024-12-31
$4.27
Market cap 14.5M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $2.04 | -52.22% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $35.98 | |||
| 2020 | $66.41 | $58.29 | $5.32 | $0.91 | $84.86 |
| 2021 | $5.18 | $22.11 | $3.11 | $0.00 | $87.92 |
| 2022 | $2.40 | $26.40 | |||
| 2023 | $2.77 | ||||
| 2024 | $0.34 | $3.34 | $0.00 |
AI valuation
Our deep-learning model estimates BioAtla, Inc.'s (BCAB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $4.27
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.04
-52.22% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BCAB | BioAtla, Inc. | $4.27 | 14.5M | — | -52% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| VERU | Veru Inc. | $2.58 | 41.41M | +876% | — | — | — | -1.60 | 1.99 | — | -0.60 | — | 3.18 | 0.00% | — | — | -89.74% | -202.93% | -50.36% | 0.17 | — | 2.43 | 2.35 | 0.36 | -6179.00% | -10000.00% | 3756.00% | -82.38% | -3.86 | -246.33% | 0.00% | 0.00% | 4.46% | -0.86 | -0.71 | — | -15.28 |
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
- CEO
- Jay Short
- Employees
- 61
- Beta
- 1.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.04 ÷ $4.27) − 1 = -52.22% (DCF, example).